Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 22,439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathologic Processes Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

NCT04643795
View directory record Official record
Conditions
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

NCT03472495
View directory record Official record
Conditions
Atrial Fibrillation and Flutter
Interventions
Diltiazem Oral Product, Diltiazem Injectable Product
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 20, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

NCT04245839
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Fludarabine, Cyclophosphamide, JCAR017
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
23
States / cities
Santa Monica, California • Aurora, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Vitamin C & Thiamine to Treat Sepsis and Septic Shock

NCT03592277
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Vitamin C, Vitamin B1
Drug
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Not applicable Interventional Results available

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457
View directory record Official record
Conditions
HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions
Pioglitazone, Exercise training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

NCT00352612
View directory record Official record
Conditions
Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
Interventions
clindamycin, cephalexin
Drug
Lead sponsor
Aaron Chen
Other
Eligibility
6 Months to 18 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 20, 2026, 7:23 PM EDT
Terminated Not applicable Interventional

Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic

NCT04654481
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Cough, Covid19
Interventions
HCFWO, Standard Care Plus Monitoring
Device · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain

NCT01729728
View directory record Official record
Conditions
Postoperative Pain, Acute Pain
Interventions
Tapentadol
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

NCT04516967
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 7:23 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00003567
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 20, 2026, 7:23 PM EDT
Completed No phase listed Observational

ParentLink: Better and Safer Emergency Care for Children

NCT00457600
View directory record Official record
Conditions
Otitis Media, Urinary Tract Infection, Asthma, Head Injury
Interventions
patient-driven health IT product
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 12 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2007 · Synced Oct 20, 2026, 7:23 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine With Dexamethasone for Foot Surgery

NCT06465992
View directory record Official record
Conditions
Foot Surgery, Ankle Surgery, Post Operative Pain, Popliteal Nerve Block
Interventions
Exparel 266 MG Per 20 ML Injection, Bupivacaine Hcl 0.75% Inj, Dexamethasone
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure

NCT00511407
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Renal tubule assist device
Device
Lead sponsor
RenaMed Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Augusta, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 20, 2026, 7:23 PM EDT
Not listed Not applicable Interventional

The Effect of Exercise on Systemic Inflammation in Veterans With COPD and OSA

NCT03431103
View directory record Official record
Conditions
COPD, OSA, Home Exercise, Inflammation
Interventions
Exercise
Behavioral
Lead sponsor
Salem Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 20, 2026, 7:23 PM EDT
Terminated Not applicable Interventional

Reducing Hospital Falls by Empowering Nurses to Provide Ambulatory Aids

NCT03675503
View directory record Official record
Conditions
Accidental Falls, Harm Reduction
Interventions
Fall Prevention Decision Support
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 20, 2026, 7:23 PM EDT
Terminated Phase 1 Interventional

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

NCT04849273
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Advanced Solid Tumor, Metastatic Solid Tumor, ALK Gene Mutation
Interventions
TPX-0131
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 20, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional

Assessment for Implementation Methods in Sepsis

NCT05491941
View directory record Official record
Conditions
Sepsis Severe, Septic Shock
Interventions
Sepsis Bundle
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 20, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

NCT05937854
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Aurora, Colorado • Decatur, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 20, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

NCT03383094
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
Interventions
Pembrolizumab, Radiation therapy, Cisplatin
Drug · Radiation
Lead sponsor
Loren Mell, MD
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • La Jolla, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Phase 3 Interventional

MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

NCT00606866
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
placebo, Sorafenib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validation of Restaurant App

NCT06868056
View directory record Official record
Conditions
Chronic Disease
Interventions
Suite of healthy food policies
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 20, 2026, 7:23 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation

NCT03650556
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 20, 2026, 7:23 PM EDT
Terminated Phase 1 Interventional Results available

Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

NCT02187029
View directory record Official record
Conditions
Gout
Interventions
PF-06743649, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • South Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 20, 2026, 7:23 PM EDT
Recruiting No phase listed Observational

Rapid Evacuation and Access of Cerebral Hemorrhage Registry

NCT07651631
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 7:23 PM EDT